Pipeline Highlights

Our product pipeline reflects our commitment to developing innovative products that can help improve people’s lives. This page features information on many of the compounds currently in our pipeline, including those we expect to launch soon. Information on this page is current as of May 8, 2018.

Late phase

  • New Material (Ophthalmic Viscosurgical Device); Initiated IDE Study – H1 2018
  • Loteprednol Gel 0.38% (ocular inflammation); PDUFA date – February 25, 2019
  • IDP-120 (acne) Initiate Phase 3 – 2H 2018
  • IDP-123 (acne) Phase 3 topline results expected – 2H 2018
  • New Rifaximin formulation (new indication); In Process
  • IDP-126 (acne combination) Phase 2 topline results expected – 1H 2019

Upcoming approvals and launches

  • Bausch + Lomb ULTRA® contact lenses extended-wear indication – Approved May 2018
  • ALTRENO1 (IDP-121 acne lotion) – PDUFA Aug. 27, 2018
  • BRYHALI1 (IDP-122 topical treatment for psoriasis) – PDUFA Oct. 5, 2018
  • PLENVU® (NER1006) – Approved May 7, 2018; Launch expected Q3 2018
  • SiHy Daily – 4Q18 (expected in certain regions)
  • LUCEMYRA – Approved May 16, 2018; Launch expected Q3 2018

1. Provisional name.

Use of this site signifies your agreement to the Legal Notice and Privacy Policy.
Copyright © 2018 Bausch Health. All rights reserved.